CY1118670T1 - Μεθοδος παρασκευης κατιονικου λιποσωμικου παρασκευασματος που περιλαμβανει λιποφιλη ενωση - Google Patents
Μεθοδος παρασκευης κατιονικου λιποσωμικου παρασκευασματος που περιλαμβανει λιποφιλη ενωσηInfo
- Publication number
- CY1118670T1 CY1118670T1 CY20171100088T CY171100088T CY1118670T1 CY 1118670 T1 CY1118670 T1 CY 1118670T1 CY 20171100088 T CY20171100088 T CY 20171100088T CY 171100088 T CY171100088 T CY 171100088T CY 1118670 T1 CY1118670 T1 CY 1118670T1
- Authority
- CY
- Cyprus
- Prior art keywords
- preparing
- catalog
- liposome preparation
- lipophilic compound
- preparation including
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 239000002502 liposome Substances 0.000 title abstract 2
- 150000002634 lipophilic molecules Chemical class 0.000 title 1
- 125000002091 cationic group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Αποκαλύπτονται μέθοδος παρασκευής κατιονικού λιποσωμικού παρασκευάσματος που περιλαμβάνει λιπόφιλη δραστική ένωση με φυσική και χημική σταθερότητα κατά την διάρκεια της βιομηχανικής κατασκευής, φύλαξης και επανασύστασης και περαιτέρω ένα κατιονικό λιποσωμικό παρασκεύασμα λαμβανόμενο με αυτήν την μέθοδο, καθώς επίσης ειδικά κατιονικά λιποσωμικά παρασκευάσματα, καθώς επίσης φαρμακευτικές συνθέσεις.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39124602P | 2002-06-26 | 2002-06-26 | |
US39124502P | 2002-06-26 | 2002-06-26 | |
EP02018724A EP1374864A1 (en) | 2002-06-26 | 2002-08-21 | Amphiphilic taxane compositions |
EP03004744 | 2003-03-04 | ||
EP03740355.7A EP1530465B2 (en) | 2002-06-26 | 2003-06-26 | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
EP10182221.1A EP2286795B1 (en) | 2002-06-26 | 2003-06-26 | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
EP09166622.2A EP2108362B1 (en) | 2002-06-26 | 2003-06-26 | A cationic liposomal preparation comprising a taxane |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118670T1 true CY1118670T1 (el) | 2017-07-12 |
Family
ID=43384485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100088T CY1118670T1 (el) | 2002-06-26 | 2017-01-20 | Μεθοδος παρασκευης κατιονικου λιποσωμικου παρασκευασματος που περιλαμβανει λιποφιλη ενωση |
Country Status (12)
Country | Link |
---|---|
US (4) | US7794747B2 (el) |
EP (4) | EP1530465B2 (el) |
JP (1) | JP4975964B2 (el) |
AT (1) | ATE444062T1 (el) |
AU (1) | AU2003280505B2 (el) |
CA (1) | CA2491216C (el) |
CY (1) | CY1118670T1 (el) |
DE (1) | DE60329497D1 (el) |
DK (2) | DK2286795T3 (el) |
ES (1) | ES2331791T5 (el) |
PT (1) | PT1530465E (el) |
WO (1) | WO2004002468A1 (el) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003039713A1 (en) | 2001-10-19 | 2003-05-15 | Innovative Construction And Building Materials, Llc | Anti-pathogenic air filtration media and air handling devices having protective capabilities against infectious airborne microorganisms |
AU2003280505B2 (en) | 2002-06-26 | 2009-01-15 | Syncore Biotechnology Co., Ltd | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
US6902797B2 (en) * | 2002-11-12 | 2005-06-07 | Innovative Construction And Building Materials | Gypsum-based composite materials reinforced by cellulose ethers |
CA2542217C (en) * | 2003-10-15 | 2018-03-27 | Medigene Ag | Method of administering cationic liposomes comprising an active drug |
EP1676569A1 (en) * | 2004-12-30 | 2006-07-05 | Pevion Biotech Ltd. | Lyophilization of virosomes |
AU2006243337B2 (en) | 2005-05-04 | 2011-09-29 | Syncore Biotechnology Co., Ltd | Method of administering a cationic liposomal preparation comprising paclitaxel |
CN100409846C (zh) * | 2005-11-22 | 2008-08-13 | 菏泽睿鹰制药集团有限公司 | 一种埃坡霉素b脂质体制剂及应用 |
CA2922029C (en) | 2006-03-22 | 2017-11-28 | Medigene Ag | A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent |
WO2008052766A2 (en) * | 2006-11-03 | 2008-05-08 | Medigene Ag | Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases |
WO2008091569A2 (en) * | 2007-01-23 | 2008-07-31 | Dtherapeutics, Llc | Devices, systems, and methods for promoting endothelialization |
WO2008114274A1 (en) * | 2007-03-19 | 2008-09-25 | Fresenius Kabi Onclology Ltd. | Proliposomal and liposomal compositions |
US20120100067A1 (en) * | 2008-04-04 | 2012-04-26 | Medigene Ag | Solubilisation Method |
AU2010227549B2 (en) * | 2009-03-25 | 2014-02-27 | Novartis Ag | Pharmaceutical composition containing a drug and siRNA |
US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
US9402812B2 (en) | 2009-09-23 | 2016-08-02 | Indu JAVERI | Methods for the preparation of liposomes |
EP2394640A1 (en) * | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
DE102011114951A1 (de) * | 2011-10-06 | 2013-04-11 | Forschungszentrum Jülich GmbH | Molekülmischung, umfassend eine amphipathische Molekülsorte A, welche im hydrophilen Bereich elne positive Gesamtladung aufweist und eine amphipathische Molekülsorte B sowie ein Polyphenol C, Verfahren zur Herstellung der Molekülmischung und deren Verwendung |
CN103110931B (zh) * | 2013-03-19 | 2015-08-19 | 广州迈达康医药科技有限公司 | 制备罗咪酯肽脂质体的方法 |
WO2016045732A1 (en) * | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
JP2018507227A (ja) | 2015-03-03 | 2018-03-15 | キュアポート インコーポレイテッド | 二薬搭載リポソーム医薬製剤 |
CN107530283A (zh) | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 组合脂质体药物制剂 |
CN107530235B (zh) | 2015-04-13 | 2021-09-17 | 方丹科技国际股份有限公司 | 用于生产超小型脂质结构的一步法 |
EP3388055B1 (en) * | 2015-12-08 | 2021-11-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Method for preparing liposome |
TWI760319B (zh) | 2015-12-30 | 2022-04-11 | 杏國新藥股份有限公司 | 乳癌治療 |
CN105853403B (zh) * | 2016-05-09 | 2019-03-29 | 上海天氏利医药科技有限公司 | 一种紫杉醇棕榈酸酯脂质体及其制备方法 |
TW201825087A (zh) | 2017-01-05 | 2018-07-16 | 杏國新藥股份有限公司 | 胰臟癌治療 |
WO2020023092A2 (en) * | 2018-04-25 | 2020-01-30 | The Johns Hopkins University | Alpha particle formulations for treatment of solid tumors |
CN110974972B (zh) * | 2019-12-03 | 2023-01-20 | 沈阳药科大学 | 难溶性药物的弱酸性衍生物及其脂质体制剂 |
CN110981837A (zh) * | 2019-12-03 | 2020-04-10 | 沈阳药科大学 | 紫杉醇弱酸性衍生物主动载药脂质体及其制备与应用 |
WO2021255262A1 (en) | 2020-06-19 | 2021-12-23 | Sylentis Sau | siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES |
EP4015634A1 (en) | 2020-12-15 | 2022-06-22 | Sylentis, S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases |
WO2023070133A2 (en) * | 2021-10-22 | 2023-04-27 | Ohio State Innovation Foundation | Compositions and methods of the delivery of active agents including nucleic acids |
US20240108579A1 (en) | 2021-12-31 | 2024-04-04 | Chengdu Biostar Pharmaceuticals, Ltd. | Utidelone liposome composition, and preparation method therefor and use thereof |
WO2024044370A1 (en) * | 2022-08-25 | 2024-02-29 | Ohio State Innovation Foundation | Compositions and methods for the delivery of active agents including nucleic acids |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
US5549910A (en) * | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
PT706373E (pt) * | 1992-03-23 | 2000-11-30 | Univ Georgetown | Taxol encapsulado num liposoma e um metodo |
FR2696458B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Procédé de préparation de dérivés du taxane. |
DE69320206T2 (de) * | 1992-11-27 | 1999-02-11 | Napro Biotherapeutics Inc | Paclitaxel enthaltende injizierbare zusammensetzung |
JPH06211645A (ja) * | 1993-01-14 | 1994-08-02 | Mitsubishi Kasei Corp | リポソーム凍結乾燥製剤 |
WO1994026254A1 (en) | 1993-05-17 | 1994-11-24 | The Liposome Company, Inc. | Incorporation of taxol into liposomes and gels |
EP0711158B2 (en) | 1993-07-29 | 2008-07-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of treating atherosclerosis or restenosis using microtubule stabilizing agent |
US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
DE4447770C2 (de) | 1994-08-20 | 2002-12-19 | Max Delbrueck Centrum | Verfahren zur Herstellung von liposomal verkapseltem Taxol |
DE4432378A1 (de) | 1994-09-12 | 1996-03-14 | Bayer Ag | Injizierbare liposomale Arzneizubereitungen |
US5821263A (en) | 1996-08-26 | 1998-10-13 | Bristol-Myers Squibb Company | Sulfenamide taxane derivatives |
WO1998017256A1 (en) * | 1996-10-22 | 1998-04-30 | Dmitri Kirpotin | Compound-loaded liposomes and methods for their preparation |
AU4966597A (en) | 1996-11-19 | 1998-06-10 | Daiichi Pharmaceutical Co., Ltd. | Taxol derivatives |
US5977386A (en) | 1996-12-24 | 1999-11-02 | Bristol-Myers Squibb Company | 6-thio-substituted paclitaxels |
US6034072A (en) * | 1997-02-10 | 2000-03-07 | Genemedicine, Inc. | IL-2 gene expression and delivery systems and uses |
US7112338B2 (en) * | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
US5837283A (en) * | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
US6287591B1 (en) | 1997-05-14 | 2001-09-11 | Inex Pharmaceuticals Corp. | Charged therapeutic agents encapsulated in lipid particles containing four lipid components |
TWI225412B (en) * | 1997-06-23 | 2004-12-21 | Sequus Pharm Inc | Liposome-entrapped polynucleotide composition and method |
US7288665B1 (en) | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
JPH1192468A (ja) | 1997-09-17 | 1999-04-06 | Yakult Honsha Co Ltd | 新規なタキサン誘導体 |
WO1999018113A1 (fr) | 1997-10-08 | 1999-04-15 | Bio Research Corporation Of Yokohama | Derives taxoides et leur procede de production |
GB9813100D0 (en) * | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
IT1306129B1 (it) * | 1999-04-13 | 2001-05-30 | Sigma Tau Ind Farmaceuti | Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti |
ES2251134T3 (es) * | 1999-06-08 | 2006-04-16 | Gentium S.P.A. | Uso de complejos entre liposomas cationicos y polidesoxirribonucleotidos como medicamentos. |
IL147089A0 (en) | 1999-07-15 | 2002-08-14 | Inex Pharmaceuticals Corp | Methods of preparing lipid-encapsulated therapeutic agents |
GB9918429D0 (en) | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
BR0013866A (pt) * | 1999-09-09 | 2002-05-14 | Univ California | Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicos |
WO2001025223A1 (en) * | 1999-10-06 | 2001-04-12 | The Research Foundation Of State University Of New York | Stabilization of taxane-containing dispersed systems |
WO2001056548A2 (en) | 2000-02-04 | 2001-08-09 | Lipoxen Technologies Limited | Liposomes composition produced by a dehydration-rehydration process |
JP2004511426A (ja) * | 2000-05-03 | 2004-04-15 | ミュンヘン バイオテク アーゲー | 活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬 |
CA2411542A1 (en) | 2000-06-09 | 2001-12-13 | Teni Boulikas | Encapsulation of polynucleotides and drugs into targeted liposomes |
US6680068B2 (en) * | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
AU2003280505B2 (en) * | 2002-06-26 | 2009-01-15 | Syncore Biotechnology Co., Ltd | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
ITPD20020271A1 (it) * | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. |
-
2003
- 2003-06-26 AU AU2003280505A patent/AU2003280505B2/en not_active Ceased
- 2003-06-26 JP JP2004548888A patent/JP4975964B2/ja not_active Expired - Fee Related
- 2003-06-26 DK DK10182221.1T patent/DK2286795T3/en active
- 2003-06-26 AT AT03740355T patent/ATE444062T1/de active
- 2003-06-26 EP EP03740355.7A patent/EP1530465B2/en not_active Expired - Lifetime
- 2003-06-26 ES ES03740355.7T patent/ES2331791T5/es not_active Expired - Lifetime
- 2003-06-26 CA CA2491216A patent/CA2491216C/en not_active Expired - Lifetime
- 2003-06-26 EP EP10182221.1A patent/EP2286795B1/en not_active Expired - Lifetime
- 2003-06-26 EP EP09166622.2A patent/EP2108362B1/en not_active Expired - Lifetime
- 2003-06-26 EP EP10182240A patent/EP2277507A1/en not_active Withdrawn
- 2003-06-26 WO PCT/EP2003/006759 patent/WO2004002468A1/en active Application Filing
- 2003-06-26 PT PT03740355T patent/PT1530465E/pt unknown
- 2003-06-26 DE DE60329497T patent/DE60329497D1/de not_active Expired - Lifetime
- 2003-06-26 DK DK03740355.7T patent/DK1530465T4/en active
-
2004
- 2004-12-22 US US11/018,574 patent/US7794747B2/en not_active Expired - Fee Related
-
2010
- 2010-08-18 US US12/859,000 patent/US8075913B2/en not_active Expired - Fee Related
-
2011
- 2011-10-21 US US13/278,801 patent/US8663606B2/en not_active Expired - Lifetime
-
2014
- 2014-01-24 US US14/163,922 patent/US9238021B2/en not_active Expired - Fee Related
-
2017
- 2017-01-20 CY CY20171100088T patent/CY1118670T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2108362A3 (en) | 2010-12-15 |
US7794747B2 (en) | 2010-09-14 |
DK2286795T3 (en) | 2017-02-06 |
EP2108362B1 (en) | 2013-05-29 |
EP2286795B1 (en) | 2016-10-26 |
AU2003280505A1 (en) | 2004-01-19 |
CA2491216A1 (en) | 2004-01-08 |
EP2108362A2 (en) | 2009-10-14 |
DE60329497D1 (de) | 2009-11-12 |
EP1530465A1 (en) | 2005-05-18 |
CA2491216C (en) | 2012-01-03 |
US9238021B2 (en) | 2016-01-19 |
US20110038926A1 (en) | 2011-02-17 |
EP1530465B2 (en) | 2015-12-16 |
US20140205657A1 (en) | 2014-07-24 |
ES2331791T3 (es) | 2010-01-15 |
WO2004002468A1 (en) | 2004-01-08 |
AU2003280505B2 (en) | 2009-01-15 |
DK1530465T3 (da) | 2010-02-01 |
ATE444062T1 (de) | 2009-10-15 |
DK1530465T4 (en) | 2016-03-21 |
US20050202076A1 (en) | 2005-09-15 |
ES2331791T5 (es) | 2016-01-21 |
US8663606B2 (en) | 2014-03-04 |
EP2277507A1 (en) | 2011-01-26 |
US20120087975A1 (en) | 2012-04-12 |
US8075913B2 (en) | 2011-12-13 |
JP2005535730A (ja) | 2005-11-24 |
JP4975964B2 (ja) | 2012-07-11 |
PT1530465E (pt) | 2010-01-05 |
EP1530465B1 (en) | 2009-09-30 |
EP2286795A1 (en) | 2011-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118670T1 (el) | Μεθοδος παρασκευης κατιονικου λιποσωμικου παρασκευασματος που περιλαμβανει λιποφιλη ενωση | |
DE60123583D1 (de) | Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome | |
ATE429901T1 (de) | Selbstformende thermodynamisch stabile liposome | |
DK1257299T3 (da) | Radioaktive, terapeutiske liposomer | |
WO2002072011A3 (en) | Stabilized therapeutic and imaging agents | |
DE69828624D1 (de) | Biologisch aktive verbindungen enthaltende multilamellare koaleszenzvesikel (mlcv) | |
ATE79028T1 (de) | Nystatin enthaltende liposome. | |
NZ538179A (en) | Liposome or lipid complex with active platinum compound and process for producing the same | |
WO2004055005A8 (en) | Novel compounds having selective inhibiting effect at gsk3 | |
DK0734252T3 (da) | Vincaalkaloidvesikler med forøget effektivitet og tumormålsøgningsegenskaber | |
CY1110258T1 (el) | Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης | |
DE69837819D1 (de) | Kondensierte plasmid-liposome komplex zur transfektion | |
BRPI0417339A (pt) | cápsula macia de butilftalida e processo para preparação da mesma | |
BR0111541A (pt) | Formulações lipossÈmicas inibidoras de timidilato sintase de benzoquinazolina | |
NO20023139D0 (no) | Liposomer som inneholder en forbindelse i supermettet lösning | |
CY1114357T1 (el) | Κατιονικο λιποσωμικο παρασκευασμα που περιλαμβανει ταξανιο | |
ES2159488B1 (es) | Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica. | |
EP0198765A3 (en) | Preparation of liposomes | |
EA200501252A1 (ru) | Липосомальная композиция, способ ее получения и лекарственное средство на ее основе (варианты) | |
NO20013015L (no) | Liposominfluminsyre - ny transdermal antiinflammatorisk medisin | |
DE69738416D1 (de) | Liposomale zubereitungen von indolocarbazol-derivaten | |
BR0106120A (pt) | Processo para produção de isolongifolanol | |
DE60313031D1 (de) | Hefebehandlung | |
WO2002009672A1 (fr) | Liposome gelatineux compose, sa composition et ses applications | |
ATE318834T1 (de) | Lipide mit aminoxygruppe |